{"commentary":{"count":11,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":6,"podcast":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02494570\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"AMPECT","nct_id":"NCT02494570","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=ampect-nct02494570. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–12 commentary sources"},"registry":{"acronym":"AMPECT","arms":[{"description":"Patients with malignant PEComa received nab-sirolimus on Days 1 and 8 of every 21-day cycle, as a 30-minute IV infusion.","label":"nab-Sirolimus","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2022-04","type":"ACTUAL"},"conditions":["Malignant PEComa"],"enrollment":{"count":34,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"nab-Sirolimus","type":"DRUG"}],"last_update":"2023-04-07","lead_sponsor":"Aadi Bioscience, Inc.","official_title":"A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-sirolimus) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-11","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Overall Response Rate (ORR)","timeFrame":"through study completion (up to 72 months)"}],"references":[{"citation":"Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Polson KM, Yalamanchili S, DeBoer C, Ding L, Schmid AN, Navarro WH, Kwiatkowski DJ, Dickson MA. A plain language summary of the AMPECT study: nab-sirolimus for advanced malignant perivascular epithelioid cell tumors. Future Oncol. 2026 Jan;22(1):1-13. doi: 10.1080/14796694.2025.2574811. Epub 2025 Dec 22.","pmid":"41424265","type":"DERIVED"},{"citation":"Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Ding L, Schmid AN, Navarro WH, Kwiatkowski DJ, Dickson MA. Phase II Trial of nab-Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update. J Clin Oncol. 2024 May 1;42(13):1472-1476. doi: 10.1200/JCO.23.02266. Epub 2024 Mar 1.","pmid":"38427923","type":"DERIVED"},{"citation":"Wagner AJ, Ravi V, Riedel RF, Ganjoo K, Van Tine BA, Chugh R, Cranmer L, Gordon EM, Hornick JL, Du H, Grigorian B, Schmid AN, Hou S, Harris K, Kwiatkowski DJ, Desai NP, Dickson MA. nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors. J Clin Oncol. 2021 Nov 20;39(33):3660-3670. doi: 10.1200/JCO.21.01728. Epub 2021 Oct 12.","pmid":"34637337","type":"DERIVED"}],"start_date":{"date":"2015-10"},"study_type":"INTERVENTIONAL","title":"A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa","url":"https://clinicaltrials.gov/study/NCT02494570"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ampect-nct02494570"}